ACC 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk (Continued)
Dr Matthew Budoff presents his results from a CT study looking at the effect of IPE +/- PCSK9 inhibitor compared with statin monotherapy on plaque progression in CAD patients and, reflects on recent results from the EVAPORATE trial, which together, provide further insight into the mechanistic basis of plaque regression mediated by IPE.
Filmed onsite at ACC 2025, this on-demand series features key insights from Dr Matthew Budoff and Prof Philippe Gabriel Steg to interpret the latest data on icosapent ethyl (IPE), including a new analysis from the REDUCE-IT trial on baseline LDL-C, two new meta-analyses and a retrospective study on plaque progression in patients treated with IPE and a PCSK9 inhibitor.
In these concise summaries, the faculty explore the impact of IPE on residual risk and provide some insight on how its effect on lipid profiles may explain what can be seen at the mechanistic level - i.e. at the level of plaque progression and plaque volume.
For more like this, you can also visit the previous highlights videos here: ACC 2025 Highlights - Prof Gabriel Steg and Dr Matthew Budoff
Educational Objective
- To provide an update and expert perspectives on recent clinical data from the REDUCE-IT trial, meta-analysis and systematic reviews on novel data with icosapent-ethyl.
Target Audience
- Cardiologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
Impact of Icosapent Ethyl and PCSK9 Inhibition on Plaque Progression in CAD
Dr Matthew Budoff presents his results from a CT study looking at the effect of IPE +/- PCSK9 inhibitor compared with statin monotherapy on plaque progression in CAD patients and, reflects on recent results from the EVAPORATE trial, which together, provide further insight into the mechanistic basis of plaque regression mediated by IPE.
Part 2
Icosapent Ethyl: An Update From REDUCE-IT and New Meta-analyses
Prof Gabriel Steg presents a new analysis from REDUCE-IT, looking at the effect of IPE across different baseline LDL-C and reviews results from two new meta-analyses on impact of IPE on MACE and lipid profiles.
Faculty Biographies
Matthew J Budoff
Professor of Medicine and Program Director and Director of Cardiac CT
Dr Matthew J Budoff, MD is a Professor of Medicine at the David Geffen School of Medicine at UCLA and the Director of Cardiac CT at Harbor-UCLA Medical Center in Torrance, CA.
Dr Budoff has conducted extensive research over the last 15 years using electron beam CT and multi-detector CT to identify those patients at high-risk for cardiac events, progression of coronary calcium, and non-invasive CT angiography.
He is the Vice President of the Society of Atherosclerosis Imaging (SAI) and a founding Board Member of the Society of Cardiovascular CT (SCCT). Previously, he served as chair of the ACC/AHA Competency document for cardiac CT and MR; the COCATS 2–CT Section (ACC training for fellows); as well as the AHA Scientific Statement on Cardiac CT.
Dr Budoff is an author of the updated Guidelines for Use of CT for Calcium Assessment and the competency guidelines for peripheral CT and MRI. Dr Budoff is a cum laude graduate of the…